An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
Abstract Background Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking.Methods Our study (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04252885">NCT04252885</jats:ext-link>, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19.Findings This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34 randomly assigned to receive LPV/r, 35 to arbidol and 17 with no antiviral medication as control. Baseline characteristics of the three groups were comparable. The primary endpoints, the average time of positive-to-negative conversion of SARS-CoV-2 nucleic acid and conversion rates at days 7 and 14, were similar between groups (all P>0.05). There were no differences between groups in the secondary endpoints, the rates of antipyresis, cough alleviation, or improvement of chest CT at days 7 or 14 (all P>0.05). At day 7, eight (23.5%) patients in the LPV/r group, 3 (8.6%) in the arbidol group and 2(11.8%) in the control group showed a deterioration in clinical status from moderate to severe/critical(P =0.206). Overall, 12 (35.3%) patients in the LPV/r group and 5 (14.3%) in the arbidol group experienced adverse events during the follow-up period. No apparent adverse event occurred in the control group.Conclusions LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care.Funding This study was supported by project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021)..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
bioRxiv.org - (2020) vom: 21. Nov. Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Yueping [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2020.03.19.20038984 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI000812536 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI000812536 | ||
003 | DE-627 | ||
005 | 20230429085954.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200327s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2020.03.19.20038984 |2 doi | |
035 | |a (DE-627)XBI000812536 | ||
035 | |a (DE-599)biorXiv10.1101/2020.03.19.20038984 | ||
035 | |a (biorXiv)10.1101/2020.03.19.20038984 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Li, Yueping |e verfasserin |4 aut | |
245 | 1 | 0 | |a An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking.Methods Our study (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04252885">NCT04252885</jats:ext-link>, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19.Findings This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34 randomly assigned to receive LPV/r, 35 to arbidol and 17 with no antiviral medication as control. Baseline characteristics of the three groups were comparable. The primary endpoints, the average time of positive-to-negative conversion of SARS-CoV-2 nucleic acid and conversion rates at days 7 and 14, were similar between groups (all P>0.05). There were no differences between groups in the secondary endpoints, the rates of antipyresis, cough alleviation, or improvement of chest CT at days 7 or 14 (all P>0.05). At day 7, eight (23.5%) patients in the LPV/r group, 3 (8.6%) in the arbidol group and 2(11.8%) in the control group showed a deterioration in clinical status from moderate to severe/critical(P =0.206). Overall, 12 (35.3%) patients in the LPV/r group and 5 (14.3%) in the arbidol group experienced adverse events during the follow-up period. No apparent adverse event occurred in the control group.Conclusions LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care.Funding This study was supported by project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021). | ||
700 | 1 | |a Xie, Zhiwei |e verfasserin |4 aut | |
700 | 1 | |a Lin, Weiyin |e verfasserin |4 aut | |
700 | 1 | |a Cai, Weiping |e verfasserin |4 aut | |
700 | 1 | |a Wen, Chunyan |e verfasserin |4 aut | |
700 | 1 | |a Guan, Yujuan |e verfasserin |4 aut | |
700 | 1 | |a Mo, Xiaoneng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yaping |e verfasserin |4 aut | |
700 | 1 | |a Peng, Ping |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xudan |e verfasserin |4 aut | |
700 | 1 | |a Hong, Wenxin |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Guangming |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jinxin |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Lieguang |e verfasserin |4 aut | |
700 | 1 | |a Hu, Fengyu |e verfasserin |4 aut | |
700 | 1 | |a Li, Feng |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Fuchun |e verfasserin |4 aut | |
700 | 1 | |a Deng, Xilong |e verfasserin |4 aut | |
700 | 1 | |a Li, Linghua |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 21. Nov. |
773 | 1 | 8 | |g year:2020 |g day:21 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.03.19.20038984 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 21 |c 11 | ||
953 | |2 045F |a 570 |